Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Preclinical overview of nepicastat cardiovascular effects

July 14, 1998

VALUE study now under way in Canada

July 10, 1998

PDE V inhibitors for heart failure, impotence claimed by Merck KGaA

July 8, 1998

Selective inhibition of MMP activity as a novel treatment for DCM

July 8, 1998

Phase I/II trial of gene therapy to treat peripheral vascular disease

July 7, 1998

ACAT inhibitors from SS Pharm. for atherosclerosis

July 7, 1998

Further data support development of TAS-301 for restenosis

July 3, 1998

BO-653: an antioxidant with potential in restenosis

July 3, 1998

LXR Biotechnology implements strategic development plan

July 2, 1998

Ferulinolol, a highly selective beta1-adrenoceptor blocker

July 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...